Impact of Intravenous Nitroglycerin in the Management of Acute Decompensated Heart Failure
- 1.2k Downloads
Intravenous nitroglycerin is a well-known, but underused, treatment for acute decompensated heart failure. Nitroglycerin has a rapid onset of action and short half-life and there is a clear dose-response curve on both global hemodynamics and peripheral circulation. IV nitroglycerin reduces LV and RV filling pressures and afterload. In the case of acute decompensated heart failure, there is a typical decreased bioavailability of nitric oxide (NO), which needs to be supplemented by exogenous nitrates. Additionally, there is benefit on clinical endpoints, such as fast optimization of arterial oxygenation, lower rates of mechanical ventilation, and improved survival. Drawbacks of therapy include not only side effects such as headache, resistance, and development of tolerability to nitrates but also free radical production. However, nitrates in combination with diuretics remain the cornerstone of acute decompensated heart failure treatment. We propose a more aggressive use of nitrates and a more limited use of inotropes (due to ischemic demand and pro-arrhythmogenic characteristics) in normo- or hypertensive patients with acute heart failure.
KeywordsAcute heart failure Critical care Emergency care Hemodynamics Inodilators Intensive care Microcirculation Nitrates Nitroglycerin Perfusion Vasodilators
Compliance with Ethics Guidelines
Conflict of Interest
Corstiaan A. den Uil and Jasper J. Brugts declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.•Singer AJ, Skopicki H, Thode HC, Peacock WK. Hemodynamic profiles of ED patients with acute decompensated heart failure and their association with treatment. Am J Emerg Med. 2014;32:302–5. This study is an example of the fact that less than 50 % of patients with acute decompensated heart failure is currently treated with vasodilators.PubMedCrossRefGoogle Scholar
- 3.Mentz RJ, Cotter G, Cleland JG, Stevens SR, Chiswell K, et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail. 2014;16:614–24.PubMedCrossRefGoogle Scholar
- 4.•Tarvasmäki T, Harjola VP, Tolonen J, Siirilä-Waris K, Nieminen MS, et al. Management of acute heart failure and the effect of systolic blood pressure on the use of intravenous therapies. Eur Heart J Acute Cardiovasc Care. 2013;2:219–25. This study is an example of the fact that less than 50 % of patients with acute decompensated heart failure is currently treated with vasodilators.PubMedCentralPubMedCrossRefGoogle Scholar
- 19.•Munzel T, Daiber A, Gori T. Good review article on the current evidence for mode of action of nitrates and the development of tolerance. Circulation. 2011;123:2132–44. Good review article on the current evidence for mode of action of nitrates and the development of tolerance.PubMedCrossRefGoogle Scholar
- 27.Verma SP, Silke B, Hussain M, Nelson GI, Reynolds GW, et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol. 1987;10:38–46.PubMedCrossRefGoogle Scholar
- 37.VMAC. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–40.Google Scholar
- 39.Costanzo MR, Johannes RS, Pine M, Gupta V, Saltzberg M, et al. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J. 2007;154:262–77.CrossRefGoogle Scholar
- 45.Daiber A, Oelze M, Coldewey M, Kaiser K, Huth C, et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun. 2005;338:1865–74.PubMedCrossRefGoogle Scholar
- 48.Cohn JN, Tam SW, Anand IS, Taylor SH, Sabolinski ML, et al. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail. 2007;13:331–9.PubMedCrossRefGoogle Scholar